• Agenda At-a-Glance*

    * Please note the track order below does not reflect the individual agendas for each live course. Please see the live course locations tab for a detailed agenda.

    Women's Cancers Track

    Ovarian Cancer:
    Molecular Advances and Emerging Treatment Strategies


    HER2-Positive and Triple-Negative Breast Cancers: New Clinical Data and Current Expert Recommendations


    Hormone Receptor Positive Breast Cancer and Hereditary Breast Cancer Syndromes: Updates on Management

    Supportive Care Track

    Supportive and Palliative Care: Managing Symptoms and Toxicities to Improve Patient Outcomes


    Optimizing Outcomes for Survivors of Cancer

    Genitourinary Cancers Track

    Prostate Cancer:
    Emerging Strategies for Individualized Management


    Bladder and Renal Cancers:
    Treatment Selection in an Evolving Therapeutic Landscape

    Head, Neck and Lung Cancers Track

    Head and Neck and Thyroid Cancers:
    Current and Emerging Systemic Therapies in the Context of Multimodal Management


    Advanced and Metastatic Lung Cancer:
    Making Optimal Use of an Expanding Range of Treatment Choices

    Melanoma Cancer Track

    Melanoma:
    Evidence-Based Treatment Approaches in the Adjuvant, Advanced, and Metastatic Settings

    Sarcoma Track

    Sarcoma and GIST:
    Current Best Practices and Expanding Treatment Options

    Gastrointestinal Cancer Track

    Esophageal, Gastric, and Pancreatic Cancers:
    Incorporating New Systemic Approaches into Current Multimodal Management


    Hereditary Gastrointestinal Cancers:
    Expert-Recommended Management and New Molecular Insights


    Current Clinical Evidence on Reducing Colorectal Cancer Risk and Recurrence Through Lifestyle Changes


    Colorectal Cancer:
    Recent Advances and Evidence-Based Best Practices for Systemic Treatment

    Hematologic Malignancies Track

    Non-Hodgkin and Hodgkin Lymphoma:
    Patient Selection for Current and Emerging Treatment Approaches


    Myeloid Malignancies:
    Molecular Insights, Targeted Therapies, and Current Best Practices


    Myeloproliferative Neoplasms:
    Practical Strategies for Diagnosis, Risk Assessment, and Management


    Multiple Myeloma:
    Current Evidence-Based Management


    Chronic Lymphocytic Leukemia:
    Individualized Management Approaches and Emerging New Therapies


    Cancer Associated Venous Thromboembolism:
    Emerging Clinical Data and Evolving Best Practices


    Course Goal and Overview

    The goal of this course is to assist oncologists with assessing and improving their skills in the diagnosis, treatment, and overall management of a wide range of common cancers.

    This innovative, live two-day curriculum provides a comprehensive update of oncologic practice, including current best practices and updated guidelines, emerging clinical evidence, and recent expert opinion in nearly all major areas of practice. Highly interactive presentations are followed by lively discussion sessions, including both Q&A and panel discussion formats. Learners are encouraged to bring their most difficult cases and clinical questions, building clinical skills through exposure to practice and patient care standards set by the acknowledged master clinicians of DFCI.

    Target Audience

    This course is intended for Medical Oncologists seeking an in depth review of the latest treatment advances in oncology.


     
  • Acknowledgments

    Dana-Farber Cancer Institute gratefully acknowledges the following organizations for providing educational grants or financial support for this activity.

    AstraZeneca Pharmaceuticals

    Bayer HealthCare Pharmaceuticals Inc.

    Bristol-Myers Squibb

    Celgene Corporation

    Novartis Pharmaceuticals Corporation

    Pfizer

    This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

This website uses cookies to ensure you get the best experience on our website. For more information on the cookies we use, please reference our Privacy Policy.